Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Expenses (2016 - 2025)

CytomX Therapeutics' Operating Expenses history spans 12 years, with the latest figure at $28.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 40.08% year-over-year to $28.6 million; the TTM value through Dec 2025 reached $98.6 million, down 12.86%, while the annual FY2025 figure was $98.6 million, 12.86% down from the prior year.
  • Operating Expenses reached $28.6 million in Q4 2025 per CTMX's latest filing, up from $21.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $46.0 million in Q4 2021 to a low of $19.9 million in Q2 2025.
  • Average Operating Expenses over 5 years is $31.4 million, with a median of $29.5 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 47.78% in 2021, then tumbled 43.07% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $46.0 million in 2021, then plummeted by 35.63% to $29.6 million in 2022, then fell by 8.16% to $27.2 million in 2023, then fell by 24.98% to $20.4 million in 2024, then surged by 40.08% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Operating Expenses are $28.6 million (Q4 2025), $21.7 million (Q3 2025), and $19.9 million (Q2 2025).